Product Description

Daunorubicin, an anthracycline antibiotic and topoisomerase II inhibitor, exhibits potent antitumor activity. It is widely used in oncology research and for treating various cancers including leukemias, non-Hodgkin lymphoma, Ewing sarcoma, and Wilms' tumor. Daunorubicin inhibits DNA and RNA synthesis, with particularly pronounced effects on RNA. As a cytotoxic agent, it suppresses cancer cell viability while inducing both apoptosis and necrosis.

Screeningbio‘s K562/Daunorubicin  resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Daunorubicin (Daunomycin) is an anthracycline chemotherapeutic agent that intercalates into DNA, inhibits topoisomerase II, and generates reactive oxygen species (ROS), thereby inducing DNA double-strand breaks, oxidative stress, and apoptosis in rapidly dividing cancer cells. It is particularly effective against hematologic malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). However, the development of drug resistance remains a major challenge limiting its long-term efficacy.

Mechanistically, daunorubicin resistance arises through multiple cellular adaptations.

Upregulation of efflux transporters such as P-glycoprotein (MDR1/ABCB1) decreases intracellular drug accumulation, while alterations in topoisomerase IIα expression or activity reduce drug-target interactions. Enhanced DNA repair capacity via pathways like homologous recombination (HR) and nucleotide excision repair (NER), along with upregulation of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL) or loss of p53 function, promotes cell survival. Additionally, activation of NF-κB and PI3K/Akt signaling counteracts apoptosis, and elevated levels of intracellular glutathione (GSH) or antioxidant enzymes such as glutathione S-transferase (GST) and superoxide dismutase (SOD) neutralize ROS-mediated damage. Changes in drug sequestration into acidic organelles (e.g., lysosomes) have also been implicated in resistance.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with efflux inhibitors (e.g., verapamil, zosuquidar), targeting anti-apoptotic Bcl-2 family proteins (e.g., venetoclax in AML), inhibiting ROS detoxification pathways, or employing patient-derived resistant leukemia cell models to guide personalized therapy development.